- Report
- October 2024
- 196 Pages
Global
From €3222EUR$3,545USD£2,759GBP
€3580EUR$3,939USD£3,066GBP
- Report
- April 2025
- 175 Pages
Global
From €4081EUR$4,490USD£3,495GBP
- Report
- June 2024
- 200 Pages
Global
From €7226EUR$7,950USD£6,187GBP
- Report
- December 2024
- 332 Pages
Global
From €3815EUR$4,197USD£3,266GBP
- Report
- April 2025
- 193 Pages
Global
From €5317EUR$5,850USD£4,553GBP
- Report
- January 2025
- 255 Pages
Global
From €7226EUR$7,950USD£6,187GBP
- Report
- June 2024
- 200 Pages
Global
From €7226EUR$7,950USD£6,187GBP
- Report
- July 2024
- 100 Pages
Global
From €3409EUR$3,750USD£2,919GBP
- Report
- November 2021
- 222 Pages
Global
From €2727EUR$3,000USD£2,335GBP
- Report
- April 2023
- 501 Pages
Global
From €3181EUR$3,500USD£2,724GBP
€4545EUR$5,000USD£3,891GBP
- Drug Pipelines
- April 2024
- 60 Pages
Global
From €1818EUR$2,000USD£1,557GBP
- Drug Pipelines
- March 2021
Global
From €3181EUR$3,500USD£2,724GBP
- Report
- June 2023
- 96 Pages
Global
From €3500EUR$4,125USD£3,102GBP
- Report
- September 2022
- 83 Pages
Global
From €3181EUR$3,500USD£2,724GBP
The Blood Cancer Drug market is a subset of the Oncology Drugs market, which focuses on the treatment of cancer. Blood cancer drugs are used to treat a variety of blood cancers, including leukemia, lymphoma, and myeloma. These drugs are typically administered intravenously or orally, and may include chemotherapy, targeted therapy, and immunotherapy. Blood cancer drugs are designed to target cancer cells while minimizing damage to healthy cells, and may be used in combination with other treatments.
The Blood Cancer Drug market is highly competitive, with a number of large pharmaceutical companies offering a range of treatments. Companies in the market include Novartis, Pfizer, Bristol-Myers Squibb, Celgene, and Merck. Show Less Read more
